REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the common stock of the Company to 13 newly hired employees with a per share exercise price of $9.28, the closing trading price on the grant date. Two newly hired Vice Presidents were each granted options to purchase 45,000 shares, and one newly hired Vice President was granted options to purchase 50,000 shares. Ten non-officer employees were granted options to purchase an aggregate of 100,000 shares.
Coherus BioSciences Announces New Employment Inducement Grants
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
